LSM8 homolog, U6 small nuclear RNA associatedGenealiases: []
Q-omics provides the consensus-scored LSM8 profile across patient tissues and cancer cell-line models. LSM8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LSM8 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, LSM8 protein abundance shows 20,845 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, HNSC, and GBM as cancer lineages where LSM8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LSM8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LSM8 survival associations across molecular data types. LSM8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LSM8 RNA expression–survival associations across cancer types. High LSM8 expression shows unfavorable associations in KICH, ACC, KIRC, UVM, LGG and LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LSM8 RNA expression.
This table summarizes LSM8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LSM8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LSM8 shows higher tumor expression in HNSC, KIRC, COAD, BLCA, KIRP and LIHC. The HNSC box plot shows higher LSM8 RNA expression in tumor versus normal tissue (log2 FC = +0.861, t-test p < 0.001).
This table shows molecular features associated with LSM8 in patient tissues and cancer cell lines. In patient samples, LSM8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LSM8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
